mk-0646
mAbexperimental
Clinical trial activity
22 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
12
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2006 (NCT00701103)
Timeline
Indications
Studied for
Mechanism of action
- Insulin-like growth factor I receptorANTAGONIST
IGF1R antagonist
Dalotuzumab binds to membrane-bound IGF1R, preventing binding of the ligand IGF1 and the subsequent triggering of the PI3K/Akt signaling pathway.
IGF1R inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1743006 ↗
Also known as
- dalotuzumab
- dalotuzumab
- dalotuzumab
- dalotuzumab
- dalotuzumab
- mk0646
- mk0646
- mk0646
- mk 0646
- mk-0646
- mk-0646
- mk-0646
- mk-0646
- mk-0646
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01605396 | Phase 2 | Jul 4, 2012 | Merck |
| NCT01609231 | Phase 2 | Jul 1, 2012 | Merck |
| NCT01431547 | Phase 1 | Feb 1, 2012 | Merck |
| NCT01243762 | Phase 1 | Nov 1, 2010 | Merck |
| NCT01234857 | Phase 2 | Sep 17, 2010 | Merck |
| NCT01175291 | Phase 2 | Sep 1, 2010 | Merck, University of South Florida |
| NCT01220570 | Phase 1 | Sep 1, 2010 | Merck |
| NCT00903006 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2009 | Bristol-Myers Squibb, Commonwealth Foundation for Cancer Research, Merck, University of Texas at Houston |
| NCT00951444 | Phase 2 | Aug 1, 2009 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT00925015 | Phase 1 | Jun 1, 2009 | Merck |
| NCT00799240 | Phase 2 | Jun 1, 2009 | Merck, University of Kansas |
| NCT00729742 | Phase 1 | Feb 1, 2009 | Merck |
| NCT00869752 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2009 | Canadian Cancer Trials Group, McMaster University |
| NCT00769483 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2008 | Merck, University of Texas at Houston |
| NCT00759785 | Phase 1 | Sep 1, 2008 | Merck |
| NCT00694356 | Phase 1 | Aug 4, 2008 | Merck |
| NCT00730379 | Phase 1 | Jul 1, 2008 | Ariad Pharmaceuticals, Merck |
| NCT00654420 | Phase 2 | Mar 1, 2008 | Merck |
| NCT00610129 | Phase 2 | Jan 1, 2008 | Cornell University, Merck |
| NCT00614393 | Phase 2 | Dec 1, 2007 | Merck |
Showing 20 of 22 trials
Page 1 / 2
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 20 | 15 | 2 | 2006 |
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 1 | 2008 |
| Ariad Pharmaceuticals | For profit | 1 | 0 | 1 | 2008 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2009 |
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Commonwealth Foundation for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| McMaster University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2009 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Kansas | Academic/Hospital | 1 | 1 | 1 | 2009 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2010 |
12 organizations
Page 1 / 1